Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.

Lexicon Pharmaceuticals Inc

LXRX
0,3392
-0,0155 (-4,37%)
Ultimo aggiornamento: 16:44:56
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
07/3/202522:02EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
07/3/202514:30GLOBELexicon Pharmaceuticals to Present at the Leerink Partners..
06/3/202522:03EDGAR2Form 8-K - Current report
06/3/202522:00GLOBELexicon Pharmaceuticals Reports Fourth Quarter and Full Year..
04/3/202522:15GLOBELexicon Pharmaceuticals to Report Fourth Quarter and Full..
03/3/202522:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/3/202522:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/3/202522:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/3/202522:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/3/202522:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/3/202513:00GLOBELexicon Pharmaceuticals Announces Topline Results from Phase..
02/3/202522:13GLOBELexicon Pharmaceuticals to Announce Topline Results from..
18/2/202522:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/2/202522:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/2/202522:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/2/202522:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/2/202522:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/2/202522:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/2/202522:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/2/202522:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/2/202514:00GLOBEPublished Data in The Lancet Diabetes & Endocrinology..
21/1/202514:00GLOBELexicon Announces Virtual Webcast on LX9211 for Diabetic..
07/1/202522:08EDGAR2Form 8-K - Current report
02/1/202522:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202522:06EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/1/202522:04EDGAR2Form 8-K - Current report
02/1/202514:00GLOBELexicon Appoints Scott Coiante as Chief Financial Officer
20/12/202422:30GLOBELexicon Announces Receipt of Complete Response Letter for..
10/12/202403:33EDGAR2Form SC 13D/A - General Statement of Acquisition of..
02/12/202423:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/11/202414:00GLOBELexicon Announces Completion of Enrollment in Phase 2B..
25/11/202422:15GLOBELexicon Pharmaceuticals to Participate in December Investor..
22/11/202413:32GLOBELexicon to Reposition as Clinical Development-Focused..
20/11/202422:07EDGAR2Form 8-K - Current report
20/11/202422:05GLOBELexicon Appoints Ivan H. Cheung to Board of Directors
14/11/202414:00GLOBEPost-Hoc Analysis Demonstrating Sotagliflozin Benefits..
13/11/202413:12EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/11/202422:06EDGAR2Form 8-K - Current report
12/11/202422:05GLOBELexicon Pharmaceuticals Reports Third Quarter 2024 Financial..
06/11/202414:00GLOBELexicon Pharmaceuticals to Participate in the Jefferies..
05/11/202422:05GLOBEPublished Data in Journal of American Society of Nephrology..
05/11/202414:00GLOBELexicon Pharmaceuticals to Host Third Quarter 2024 Financial..
04/11/202414:00GLOBELexicon to Present Preclinical IN VIVO Efficacy Data..
31/10/202423:54GLOBELexicon Announces Outcome of FDA Advisory Committee for..
23/10/202415:00GLOBENew Analysis of Phase 3 Data Demonstrating Renal Protective..
22/10/202414:00GLOBELexicon Announces Completion of Screening in Phase 2B..
16/10/202422:37EDGAR2Form 8-K - Current report
16/10/202422:35GLOBELexicon Announces Exclusive Licensing Agreement With Viatris..
16/10/202422:34PRNUSViatris Announces Exclusive Licensing Agreement with Lexicon..
27/9/202414:00GLOBELexicon to Present Phase 3 Trial Design for Sotagliflozin in..
Apertura: 0,3404 Min: 0,3302 Max: 0,3539
Chiusura: 0,3547

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network